Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a lot of news and analysis today that we’ll get straight into.
The need-to-know this morning
Bristol Myers Squibb earnings can be viewed here.
Generate Biomedicines, a Flagship Pioneering AI-based drug developer, has filed to go public.
Rollout of Vertex’s CRISPR treatment faces surprising roadblock
Over two years after the approval of Vertex’s sickle cell treatment Casgevy, rollout has continued to be slow, with only about 60 patients having been treated. Specialists at more than a half-dozen sickle cell centers told STAT they’ve been surprised by a stumbling block: They can’t collect enough cells to create the treatment.Continue to STAT+ to read the full story…